Attivit dei laboratori DREAM

1
New patient, inclusive of VCT (cumulative)
2
Patients under treatment (cumulative)
3
Patients currently under treatment by age and
service 10,254
4
Patients who received an ARV treatment 7869
5
Newborn chldrens in MCPC
6
Pregnant women in MCPC (cumulative)
7
Number of visit
8
Number of blood samples for month and cumulative
9
Blood exams permofed and type
10
Problems

• Delayed or missing answer from MOH/ WB on request
  on budget re-allocation
• Lack of opportunistic infection drugs and
  apparently no chance to use them in the TAP
  funds
• Uncertain availability of second line ARV drugs
• Delayed DPSs local approval of the request
• Target of TAP program not clear at DPS level

11
Challenges

• Operational research to be implemented
• Viral monitoring
• Secure of funds for the future ( sustainability)